Table 3.

Cumulative Incidence of Infections

Infections
	N	# with infections	100 days (95% CI)	1 year (95% CI)	P	1 year competing risk (95% CI)	P
CMV infections
Total	98	16	15% (8–22%)	16% (9–23%)		30% (21–39%)
Palifermin	67	11	16% (7–25%)	16% (7–25%)	0.94	29% (18–30%)	0.65
Placebo	31	5	13% (2–24%)	16% (3–29%)		32% (15–49%)
Fungal infections
Total	98	37	28% (19–37%)	37% (27–47%)		20% (12–28%)
Palifermin	67	28	29% (18–40%)	41% (29–53%)	0.38	19% (10–28%)	0.65
Placebo	31	9	26% (11–41%)	29% (13–45%)		23% (8–38%)

The competing risks (death without infection) are shown.